KR101412881B1 - 바닐로이드 수용체 ｔｒｐｖ１과 관련된 장애의 치료에서 유용한 벤즈이미다졸 유도체 - Google Patents

바닐로이드 수용체 ｔｒｐｖ１과 관련된 장애의 치료에서 유용한 벤즈이미다졸 유도체 Download PDF

Info

Publication number
KR101412881B1
KR101412881B1 KR1020097002681A KR20097002681A KR101412881B1 KR 101412881 B1 KR101412881 B1 KR 101412881B1 KR 1020097002681 A KR1020097002681 A KR 1020097002681A KR 20097002681 A KR20097002681 A KR 20097002681A KR 101412881 B1 KR101412881 B1 KR 101412881B1
Authority
KR
South Korea
Prior art keywords
acetamide
ethyl
benzimidazol
cyano
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097002681A
Other languages
English (en)
Korean (ko)
Other versions
KR20090035701A (ko
Inventor
윌리암 브라운
숀 존스톤
데니스 라브레퀘
Original Assignee
네오메드 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39033277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101412881(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 네오메드 인스티튜트 filed Critical 네오메드 인스티튜트
Publication of KR20090035701A publication Critical patent/KR20090035701A/ko
Application granted granted Critical
Publication of KR101412881B1 publication Critical patent/KR101412881B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020097002681A 2006-08-11 2007-08-10 바닐로이드 수용체 ｔｒｐｖ１과 관련된 장애의 치료에서 유용한 벤즈이미다졸 유도체 Expired - Fee Related KR101412881B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83724906P 2006-08-11 2006-08-11
US60/837,249 2006-08-11
PCT/SE2007/000720 WO2008018827A1 (en) 2006-08-11 2007-08-10 Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders

Publications (2)

Publication Number Publication Date
KR20090035701A KR20090035701A (ko) 2009-04-10
KR101412881B1 true KR101412881B1 (ko) 2014-06-26

Family

ID=39033277

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097002681A Expired - Fee Related KR101412881B1 (ko) 2006-08-11 2007-08-10 바닐로이드 수용체 ｔｒｐｖ１과 관련된 장애의 치료에서 유용한 벤즈이미다졸 유도체

Country Status (25)

Country Link
US (2) US7906654B2 (enExample)
EP (1) EP2051967B1 (enExample)
JP (1) JP5140077B2 (enExample)
KR (1) KR101412881B1 (enExample)
CN (2) CN101792436A (enExample)
AR (1) AR062299A1 (enExample)
AU (1) AU2007282186B2 (enExample)
BR (1) BRPI0715746B8 (enExample)
CA (1) CA2660529C (enExample)
CL (1) CL2007002343A1 (enExample)
CO (1) CO6150176A2 (enExample)
ES (1) ES2533971T3 (enExample)
IL (1) IL196672A0 (enExample)
MX (1) MX2009001496A (enExample)
MY (1) MY147649A (enExample)
NO (1) NO20091054L (enExample)
NZ (1) NZ575416A (enExample)
PE (1) PE20081315A1 (enExample)
RU (1) RU2458055C2 (enExample)
SG (1) SG173360A1 (enExample)
TW (1) TWI433839B (enExample)
UA (1) UA96764C2 (enExample)
UY (1) UY30533A1 (enExample)
WO (1) WO2008018827A1 (enExample)
ZA (1) ZA200900961B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
TWI433839B (zh) * 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR101252334B1 (ko) 2008-04-18 2013-04-08 주식회사 대웅제약 신규 벤조옥사진 벤즈이미다졸 유도체, 이를 포함하는 약학 조성물 및 이의 용도
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
CN104640857B (zh) 2012-07-18 2017-07-04 圣路易斯大学 作为整合素拮抗剂的β氨基酸衍生物
JO3719B1 (ar) 2014-11-20 2021-01-31 Takeda Pharmaceuticals Co 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
JP6853778B2 (ja) 2014-12-08 2021-03-31 ローム アンド ハース カンパニーＲｏｈｍ Ａｎｄ Ｈａａｓ Ｃｏｍｐａｎｙ ポリオレフィン添加剤、耐垂下性ポリオレフィン、及びその調製方法
JP2018052817A (ja) * 2015-01-21 2018-04-05 大日本住友製薬株式会社 新規ベンズイミダゾール誘導体およびその医薬用途
HK1244806A1 (zh) 2015-12-30 2018-08-17 Saint Louis University 作為過氧乙醯硝酸整聯蛋白拮抗劑的間氮雜環氨基苯甲酸衍生物
JP2022516362A (ja) * 2019-01-08 2022-02-25 ネオメド インスティテュート－インスティテュート ネオメド （ｓ）－２－（７－シアノ－１ｈ－ベンズイミダゾール－１イル）－ｎ－｛１－［４－（１－シアノ－１－メチルエチル）フェニル］エチル｝アセトアミドの結晶形態
PH12022550597A1 (en) 2019-09-16 2024-03-04 Takeda Pharmaceuticals Co Azole-fused pyridazin-3(2h)-one derivatives
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе
CN117623972A (zh) * 2022-08-17 2024-03-01 上海慧聚药业有限公司 非离子型造影剂中间体的合成

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050031A1 (en) 2000-12-21 2002-06-27 Glaxo Group Limited Indole derivatives
WO2004100865A2 (en) 2003-05-16 2004-11-25 Astrazeneca Ab New benzimidazole derivatives
WO2006033620A1 (en) 2004-09-21 2006-03-30 Astrazeneca Ab New heterocyclic amides

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1186504A (en) 1966-10-15 1970-04-02 Fisons Pest Control Ltd Substituted Heterocyclic Compounds
IT1036004B (it) * 1968-05-21 1979-10-30 Abc Ist Biolog Chem Spa Acidt 3 indolil adetoidrossamici
BE793718A (fr) * 1972-01-07 1973-07-05 Merck & Co Inc Aminobenzimidazoles
DE3347290A1 (de) 1983-12-28 1985-07-11 Dr. Karl Thomae Gmbh, 7950 Biberach Neue 2-phenyl-imidazole, ihre herstellung und diese verbindungen enthaltende arzneimittel
US4738981A (en) * 1984-11-13 1988-04-19 Warner-Lambert Substituted trans-1,2-diaminocyclohexyl amide compounds
JP2639000B2 (ja) 1988-09-30 1997-08-06 スズキ株式会社 酸素富化エンジンの酸素富化空気制御装置
JPH0295767A (ja) 1988-09-30 1990-04-06 Showa Alum Corp 吸気マニホルド
JPH06759B2 (ja) 1989-09-22 1994-01-05 ファイザー製薬株式会社 新規なベンゾイミダゾール化合物
DE4309969A1 (de) 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
US5403851A (en) 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
WO1997024334A1 (en) 1995-12-28 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Benzimidazole derivatives
GB9713484D0 (en) 1997-06-27 1997-09-03 Smithkline Beecham Plc Neuroprotective vanilloid compounds
JP2000095767A (ja) 1998-09-28 2000-04-04 Takeda Chem Ind Ltd 性腺刺激ホルモン放出ホルモン拮抗剤
HUP0203542A3 (en) 1999-08-12 2003-07-28 Upjohn Co 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
AU2001264566A1 (en) 2000-05-05 2001-11-20 Cor Therapeutics, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
WO2001096336A2 (en) 2000-06-14 2001-12-20 Warner-Lambert Company 6,5-fused bicyclic heterocycles
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US6835752B2 (en) 2000-08-22 2004-12-28 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives, processes for the preparation thereof and pharmaceutical agents comprising the same as active ingredient
ITTO20010110A1 (it) 2001-02-08 2002-08-08 Rotta Research Lab Nuovi derivati benzamidinici dotati di attivita' anti-infiammatoria ed immunosoppressiva.
GB0105895D0 (en) 2001-03-09 2001-04-25 Smithkline Beecham Plc Novel compounds
SE0101387D0 (sv) 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
GB0110901D0 (en) 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
TWI239942B (en) * 2001-06-11 2005-09-21 Dainippon Pharmaceutical Co N-arylphenylacetamide derivative and pharmaceutical composition containing the same
US7144883B2 (en) 2001-06-11 2006-12-05 Biovitrum Ab Bicyclic sulfonamide compounds
EP1414788A1 (en) 2001-07-31 2004-05-06 Bayer HealthCare AG Naphthylurea and naphthylacetamide derivatives as vanilloid receptor 1 (vr1) antagonists
JP4059473B2 (ja) 2001-08-09 2008-03-12 株式会社ルネサステクノロジ メモリカード及びメモリコントローラ
MY138086A (en) 2001-09-13 2009-04-30 Smithkline Beecham Plc Novel urea derivative as vanilloid receptor-1 antagonist
TWI231757B (en) 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
CA2468544A1 (en) 2001-12-10 2003-06-19 Amgen Inc. Vanilloid receptor ligands
GB0130550D0 (en) 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel compounds
DE60325025D1 (de) 2002-02-15 2009-01-15 Glaxo Group Ltd Modulatoren des vanilloidrezeptors
US20030158188A1 (en) * 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
SG156524A1 (en) 2002-06-20 2009-11-26 Biovitrum Ab Publ New compounds useful for the treatment of obesity, type ii diabetes and cns disorders
FR2842069B1 (fr) 2002-07-12 2004-09-10 Pellenc Sa Effeuilleuse, plus specialement destinee a l'effeuillage selectif de la vigne
GB0221157D0 (en) 2002-09-12 2002-10-23 Glaxo Group Ltd Novel treatment
AU2003270199A1 (en) 2002-09-13 2004-04-30 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
WO2004035549A1 (en) * 2002-10-17 2004-04-29 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
SE0301701D0 (sv) 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
MXPA06002550A (es) 2003-09-03 2006-06-20 Pfizer Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4.
WO2005095327A1 (ja) * 2004-03-31 2005-10-13 Ajinomoto Co., Inc. アニリン誘導体
TW200736227A (en) 2005-12-23 2007-10-01 Astrazeneca Ab New compounds III
TWI433839B (zh) * 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002050031A1 (en) 2000-12-21 2002-06-27 Glaxo Group Limited Indole derivatives
WO2004100865A2 (en) 2003-05-16 2004-11-25 Astrazeneca Ab New benzimidazole derivatives
WO2006033620A1 (en) 2004-09-21 2006-03-30 Astrazeneca Ab New heterocyclic amides

Also Published As

Publication number Publication date
RU2009103675A (ru) 2010-09-20
CA2660529A1 (en) 2008-02-14
US8093402B2 (en) 2012-01-10
BRPI0715746B8 (pt) 2021-05-25
BRPI0715746B1 (pt) 2020-09-24
NO20091054L (no) 2009-03-09
ES2533971T3 (es) 2015-04-16
PE20081315A1 (es) 2008-11-08
AU2007282186A1 (en) 2008-02-14
UY30533A1 (es) 2008-03-31
CL2007002343A1 (es) 2008-04-04
EP2051967A1 (en) 2009-04-29
US20080221188A1 (en) 2008-09-11
UA96764C2 (ru) 2011-12-12
AR062299A1 (es) 2008-10-29
CN101522637A (zh) 2009-09-02
ZA200900961B (en) 2010-07-28
US20110137045A1 (en) 2011-06-09
US7906654B2 (en) 2011-03-15
JP2010500345A (ja) 2010-01-07
RU2458055C2 (ru) 2012-08-10
WO2008018827A1 (en) 2008-02-14
AU2007282186B2 (en) 2011-07-07
MX2009001496A (es) 2009-02-18
EP2051967A4 (en) 2011-06-29
CN101792436A (zh) 2010-08-04
TW200817338A (en) 2008-04-16
KR20090035701A (ko) 2009-04-10
IL196672A0 (en) 2009-11-18
CO6150176A2 (es) 2010-04-20
JP5140077B2 (ja) 2013-02-06
SG173360A1 (en) 2011-08-29
TWI433839B (zh) 2014-04-11
MY147649A (en) 2012-12-31
CA2660529C (en) 2014-10-21
NZ575416A (en) 2011-10-28
WO2008018827A8 (en) 2009-02-19
EP2051967B1 (en) 2014-12-31
BRPI0715746A2 (pt) 2013-07-16

Similar Documents

Publication Publication Date Title
KR101412881B1 (ko) 바닐로이드 수용체 ｔｒｐｖ１과 관련된 장애의 치료에서 유용한 벤즈이미다졸 유도체
KR100688740B1 (ko) 프로테아제 억제제로서의 ｎ-시아노메틸 아미드
EP1626964B1 (en) New benzimidazole derivatives
AU2007248341B2 (en) Benzimidazole modulators of VR1
JP4667384B2 (ja) イオンチャネルリガンドとしてのアミド誘導体および薬学的組成物、ならびにこれらを使用する方法
JP2007527363A (ja) バニロイドｖｒ１受容体のモジュレーターであるキノリン誘導アミド
MX2011006428A (es) Triazolopiridinas como inhibidores de fosfodiesterasa para tratamiento de enfermedades dermicas.
BRPI0912778B1 (pt) Composto de amida, composição farmacêutica compreendedo dito composto e uso do mesmo para o tratamento de insuficiência renal crônica ou nefropatia diabética
AU2005285656A1 (en) New heterocyclic amides
HK1085735B (en) New benzimidazole derivatives
HK1128475A (en) Benzimidazole derivatives as vanilloid receptor antagonists
WO2012013012A1 (zh) 苯并氮杂环羟乙基胺类化合物、其制备方法和用途
HK1165791B (en) Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20170619

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20190618

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20230621

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20230621